Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Susan O'Brien, Jeffrey A Jones, Steven E Coutre, Anthony R Mato, Peter Hillmen, Constantine Tam, Anders Osterborg, Tanya Siddiqi, Michael J Thirman, Richard R Furman, Osman Ilhan, Michael J Keating, Timothy G Call, Jennifer R Brown, Michelle Stevens-Brogan, Yunfeng Li, Fong Clow, Danelle F James, Alvina D Chu, Michael Hallek Show all
The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2016
We thank the patients who participated in the study, their supporters, and the investigators and clinical research staff from the study centres. This manuscript was developed with editorial support from Luana Atherly-Henderson from Nexus Global Group Science LLC and funded by Pharmacyclics LLC, an AbbVie Company.